Search - tctmd.com

Displaying 261 - 280 of 708

Sort: Relevancy | Date

Presentation TCT 2018

The WaveCrest Device and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Gregg W. Stone

September 24, 2018

Presentation TCT 2018

The Amulet Platform, Experience and US Pivotal Trial

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Apostolos Tzikas

September 24, 2018

Presentation TCT 2018

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

Presenter: Vivek Y. Reddy, Brian K. Whisenant

September 24, 2018

Presentation TCT 2018

FDA Perspectives on New Devices and Indications for LAA Closure

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Andrew Farb

September 24, 2018

Presentation TCT 2018

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Presenter: Vivek Y. Reddy, Brian K. Whisenant, Paul D. Varosy

September 24, 2018

Presentation TCT 2018

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Presenter: James B. Hermiller Jr, David Hildick-Smith, George S. Hanzel

September 24, 2018

Presentation TCT 2018

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Presenter: James B. Hermiller Jr, David Hildick-Smith, Martin W. Bergmann

September 24, 2018

Presentation TCT 2018

Essential of Pre-procedural Imaging and Intra-procedural Guidance

Presenter: James B. Hermiller Jr, David Hildick-Smith, Jacqueline Saw

September 24, 2018

Presentation TCT 2018

Shared Decision-making in NVAF: The Patients Perspective

Presenter: James B. Hermiller Jr, David Hildick-Smith, Megan Coylewright

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Presenter: James B. Hermiller Jr, David Hildick-Smith, David R. Holmes Jr.

September 24, 2018

Presentation TCT 2018

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Presenter: James B. Hermiller Jr, David Hildick-Smith, Freek W.A. Verheugt

September 24, 2018

Presentation TCT 2018

Stroke Etiology, LAA Closure, and the Therapeutic Landscape: A Neurologists Perspective

Presenter: James B. Hermiller Jr, David Hildick-Smith, David E. Thaler

September 24, 2018

News Opinion Off Script TCT 2018

Off Script: A Monumental, First-World Victory vs an Enduring First-World Failure

Kwan S. Lee

September 23, 2018

Presentation TCT 2018

LAA Closure 3: Prevention and Management of Complications

Presenter: Habib Gamra, E. Murat Tuzcu

September 23, 2018

Presentation TCT 2018

LAA Closure 2: Step-by-step

Presenter: Habib Gamra, E. Murat Tuzcu, Hazem Khamis

September 23, 2018

Presentation TCT 2018

LAA Closure 1: State-of-the-art

Presenter: Habib Gamra, E. Murat Tuzcu

September 23, 2018

Presentation TCT 2018

Take-Home Messages: What Did We Learn From These Cases?

Presenter: Maurice Buchbinder, Vivek Y. Reddy

September 23, 2018

Presentation TCT 2018

EWOLUTION: Two-Year Efficacy of Left Atrial Appendage Closure in High-Risk Patients - Single Antiplatelet/No Therapy Subgroup Analysis

Presenter: Horst Sievert, Brian K. Whisenant, Martin W. Bergmann

September 23, 2018

Presentation TCT 2018

Case #12: An LAA Exclusion Procedure Guided by Personalized Computer Modeling

Presenter: Maurice Buchbinder, Vivek Y. Reddy, Habib Gamra, Aaron V. Kaplan, Ulf Landmesser, Petr Neuzil, Jai-Wun Park, Kolja Sievert

September 23, 2018

Presentation TCT 2018

TAVI/LAAO: A Randomized Trial of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Presenter: Horst Sievert, Brian K. Whisenant, Fabian Nietlispach

September 23, 2018

Advertisement

The WaveCrest Device and US Pivotal Trial

The Amulet Platform, Experience and US Pivotal Trial

The Watchman Platform, ASAP Too and Flex: Rationale, Device and Overview of the Trials

FDA Perspectives on New Devices and Indications for LAA Closure

The LAAO Registry: Overview, Data Adjudication, and Emerging Insights

Managing a Busy LAA Closure Program: Patient Selection, Education, Consent, Screening, and Periprocedural Care

Adjunctive Pharmacology Following LAA Closure in Anticoagulant Indicated and Contraindicated Patients

Essential of Pre-procedural Imaging and Intra-procedural Guidance

Shared Decision-making in NVAF: The Patients Perspective

Debate: Is LAA Closure a Valid Alternative for Patients with No or Mild Contraindications to Anticoagulants? Yes - LAA Closure Reduces Hemorrhagic Stroke and Mortality And Nearly Everyone Has a Reason Not to Take Oral Anticoagulants!

Debate: Is LAA Closure a Valid Alternative for Patients With No or Mild Contraindications to Anticoagulants? No NOACs Are Strongly Preferred to LAA Closure!

Stroke Etiology, LAA Closure, and the Therapeutic Landscape: A Neurologists Perspective

Off Script: A Monumental, First-World Victory vs an Enduring First-World Failure

LAA Closure 3: Prevention and Management of Complications

LAA Closure 2: Step-by-step

LAA Closure 1: State-of-the-art

Take-Home Messages: What Did We Learn From These Cases?

EWOLUTION: Two-Year Efficacy of Left Atrial Appendage Closure in High-Risk Patients - Single Antiplatelet/No Therapy Subgroup Analysis

Case #12: An LAA Exclusion Procedure Guided by Personalized Computer Modeling

TAVI/LAAO: A Randomized Trial of Left Atrial Appendage Occlusion vs Standard Medical Therapy in Patients With Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content